INT135373

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.62
First Reported 2006
Last Reported 2011
Negated 1
Speculated 4
Reported most in Abstract
Documents 35
Total Number 41
Disease Relevance 18.11
Pain Relevance 3.53

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Gsk3b) carbohydrate metabolic process (Gsk3b) protein complex (Gsk3b)
response to stress (Gsk3b) cytoplasm (Gsk3b) cytosol (Gsk3b)
Anatomy Link Frequency
neuronal 1
pons 1
brain 1
medulla oblongata 1
cerebellum 1
Gsk3b (Mus musculus)
Pain Link Frequency Relevance Heat
medulla 15 100.00 Very High Very High Very High
depression 66 99.68 Very High Very High Very High
antidepressant 48 99.52 Very High Very High Very High
Neurotransmitter 29 99.42 Very High Very High Very High
Serotonin 12 98.90 Very High Very High Very High
Dopamine 30 98.76 Very High Very High Very High
Spinal cord 7 97.84 Very High Very High Very High
Hippocampus 56 97.80 Very High Very High Very High
tolerance 83 94.00 High High
antagonist 14 90.28 High High
Disease Link Frequency Relevance Heat
Disease 443 99.98 Very High Very High Very High
Affective Disorder 47 99.96 Very High Very High Very High
Schizophrenia 24 99.88 Very High Very High Very High
Depression 73 99.68 Very High Very High Very High
Mantle-cell Lymphoma 33 99.68 Very High Very High Very High
Parkinson's Disease 360 99.42 Very High Very High Very High
Targeted Disruption 365 99.36 Very High Very High Very High
Bronchopulmonary Dysplasia 54 99.28 Very High Very High Very High
Manic Depressive Disorder 54 99.20 Very High Very High Very High
Death 345 98.66 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Regulation of phospho-Ser-GSK3 was a shared effect among several atypical antipsychotics, including olanzapine, clozapine, quetiapine, and ziprasidone.
Regulation (Regulation) of GSK3
1) Confidence 0.62 Published 2007 Journal Int. J. Neuropsychopharmacol. Section Abstract Doc Link 16672106 Disease Relevance 0.40 Pain Relevance 0.32
The mechanisms of GSK-3 regulation are not fully understood; precise control appears to be achieved by a combination of phosphorylation, localization, and interactions with GSK-3-binding proteins [6].
Regulation (regulation) of GSK-3
2) Confidence 0.56 Published 2009 Journal Mol Brain Section Body Doc Link PMC2785804 Disease Relevance 0 Pain Relevance 0
Unlike classical protein kinases, GSK-3 is active under resting conditions and is primarily regulated by inactivation.
Regulation (regulated) of GSK-3
3) Confidence 0.56 Published 2009 Journal Mol Brain Section Body Doc Link PMC2785804 Disease Relevance 0.19 Pain Relevance 0.03
Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics.
Regulation (Regulation) of glycogen synthase kinase-3 in brain
4) Confidence 0.54 Published 2007 Journal Int. J. Neuropsychopharmacol. Section Title Doc Link 16672106 Disease Relevance 0.41 Pain Relevance 0.22
We previously reported that serotonin, a major neurotransmitter involved in mood disorders, regulates GSK3 by acutely increasing its N-terminal serine phosphorylation.
Regulation (regulates) of GSK3 associated with neurotransmitter, affective disorder and serotonin
5) Confidence 0.45 Published 2007 Journal Int. J. Neuropsychopharmacol. Section Abstract Doc Link 16672106 Disease Relevance 0.45 Pain Relevance 0.13
This study investigated the effects of a novel thiadiazolidinone NP031115, a putative GSK-3beta inhibitor, and the well-established GSK-3beta inhibitor AR-A014418 in the mouse forced swimming test (FST), a model widely used to evaluate antidepressant activity.
Spec (investigated) Regulation (effects) of GSK-3beta associated with antidepressant
6) Confidence 0.44 Published 2008 Journal Prog. Neuropsychopharmacol. Biol. Psychiatry Section Abstract Doc Link 18579278 Disease Relevance 0.19 Pain Relevance 0.26
This study investigated the effects of a novel thiadiazolidinone NP031115, a putative GSK-3beta inhibitor, and the well-established GSK-3beta inhibitor AR-A014418 in the mouse forced swimming test (FST), a model widely used to evaluate antidepressant activity.
Spec (investigated) Regulation (effects) of GSK-3beta associated with antidepressant
7) Confidence 0.44 Published 2008 Journal Prog. Neuropsychopharmacol. Biol. Psychiatry Section Abstract Doc Link 18579278 Disease Relevance 0.19 Pain Relevance 0.25
Effects of Lithium on GSK3?
Regulation (Effects) of GSK3
8) Confidence 0.40 Published 2007 Journal PLoS Medicine Section Body Doc Link PMC1880853 Disease Relevance 0.34 Pain Relevance 0
Slightly increased volumes of the medulla oblongata and pons in GSK-3?
Regulation (volumes) of GSK-3 in pons associated with medulla
9) Confidence 0.36 Published 2009 Journal Mol Brain Section Body Doc Link PMC2785804 Disease Relevance 0.41 Pain Relevance 0.13
Furthermore, analysis of insulin signaling in the Alb Cre + mice revealed no differences in the activation status of the insulin-regulated proteins PKB, GSK-3 and GS.
Regulation (regulated) of GSK-3
10) Confidence 0.35 Published 2011 Journal PLoS ONE Section Body Doc Link PMC3017066 Disease Relevance 0.40 Pain Relevance 0
The data from these studies support the idea that there are isoform and tissue-specific roles for GSK-3 in the regulation of glucose metabolism and insulin action, such that GSK-3?
Regulation (roles) of GSK-3
11) Confidence 0.35 Published 2011 Journal PLoS ONE Section Body Doc Link PMC3017066 Disease Relevance 0.80 Pain Relevance 0.08
The data from these studies support the idea that there are isoform and tissue-specific roles for GSK-3 in the regulation of glucose metabolism and insulin action, such that GSK-3?
Regulation (roles) of GSK-3
12) Confidence 0.35 Published 2011 Journal PLoS ONE Section Body Doc Link PMC3017066 Disease Relevance 0.73 Pain Relevance 0.08
Given the strain differences in our original analyses, we examined the insulin and glucose sensitivity of global GSK-3?
Spec (examined) Regulation (sensitivity) of GSK-3 associated with sprains and strains
13) Confidence 0.30 Published 2011 Journal PLoS ONE Section Abstract Doc Link PMC3017066 Disease Relevance 0.73 Pain Relevance 0.05
Therefore, proper control of GSK3 by serine-phosphorylation, which is targeted by agents therapeutic for bipolar disorder, is an important mechanism that regulates mood stabilization, and mice with disabled GSK3 serine-phosphorylation may provide a valuable model to study bipolar disorder.
Regulation (control) of GSK3 associated with manic depressive disorder
14) Confidence 0.27 Published 2010 Journal Neuropsychopharmacology Section Abstract Doc Link 20357757 Disease Relevance 0.75 Pain Relevance 0.03
The present study was undertaken to further determine if atypical antipsychotics, which have therapeutic effects in both mood disorders and schizophrenia, can regulate phospho-Ser-GSK3 and inhibit its activity.
Regulation (regulate) of GSK3 associated with affective disorder and schizophrenia
15) Confidence 0.27 Published 2007 Journal Int. J. Neuropsychopharmacol. Section Abstract Doc Link 16672106 Disease Relevance 0.46 Pain Relevance 0.26
Accumulating evidence implicates abnormal activity of GSK3 in mood disorders and schizophrenia, and GSK3 is a potential protein kinase target for psychotropics used in these disorders.
Regulation (target) of GSK3 associated with affective disorder and schizophrenia
16) Confidence 0.27 Published 2007 Journal Int. J. Neuropsychopharmacol. Section Abstract Doc Link 16672106 Disease Relevance 0.43 Pain Relevance 0.12
These results confirm GSK3 as a plausible target of lithium action in BPD therapeutics, and suggest the circadian clock mechanism as a significant modulator of lithium's clinical benefits.



Regulation (target) of GSK3 associated with bronchopulmonary dysplasia
17) Confidence 0.26 Published 2007 Journal J Circadian Rhythms Section Abstract Doc Link PMC1803776 Disease Relevance 0.32 Pain Relevance 0.05
Lithium, a direct inhibitor of glycogen synthase kinase 3 (GSK3) activity, and a mainstay in BPD therapeutics, has been proposed to target GSK3 as a mechanism of mood stabilization.
Regulation (target) of GSK3 associated with bronchopulmonary dysplasia
18) Confidence 0.26 Published 2007 Journal J Circadian Rhythms Section Abstract Doc Link PMC1803776 Disease Relevance 0.64 Pain Relevance 0.05
The effect of kenpaullone on GSK3 activity has been shown to be slow and gradual in various cell lines [50], and may account, at least in part, for the latency observed herein.


Regulation (effect) of GSK3
19) Confidence 0.26 Published 2007 Journal J Circadian Rhythms Section Body Doc Link PMC1803776 Disease Relevance 0.14 Pain Relevance 0
Moreover, we showed that the regulation of GSK-3?
Regulation (regulation) of GSK-3
20) Confidence 0.24 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2675062 Disease Relevance 0.42 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox